Spyre Therapeutics, Inc. cotiza a 85.69 USD y tiene una capitalización bursátil de $7.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selecti…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.36 | $-0.74 | $-0.74 |
| Estimado | $-0.83 | $-0.75 | $-0.65 | $-0.80 |
| Sorpresa | — | +52.0% | -13.8% | +7.5% |
| Métrica | SYRE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -21.7% | -40.4% | +18.7% |
| ROA | -19.9% | -32.0% | +12.1% |
| Current Ratio | 13.25 | 2.84 | +10.41 |
| Debt / Equity | — | 0.28 | — |